Clinical trials: Treatment Resistant Major Depression
Treatment Resistant Depression
Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression: OL Cohort
This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial magnetic stimulation device for treatment-resistant depression.
- Trial name
- SAINT-TRD (NCT03240692)
- Testing
- Accelerated theta-burst stimulation treatment
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Stanford University
Major Depressive Disorder
5-hydroxytryptophan and Creatine for Treatment Resistant Depression Associated With Hypoxia in Females
The investigators hypothesize that the administration of two widely available, naturally occurring dietary supplements, 5 hydroxytryptophan and creatine monohydrate, will reduce the severity of depression in individuals exposed…
- Trial name
- NCT02356107
- Testing
- 5-hydroxytryptophan and Creatine monohydrate
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Perry Renshaw
Treatment Resistant Major Depressive Disorder
This is a Study to Determine the Antidepressant Effects of AZD6765
The purpose of this study is to determine the antidepressant effects of AZD6765 compared to placebo.
- Trial name
- NCT00986479
- Testing
- AZD6765
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
Ketamine Infusion for Treatment-resistant Major Depressive Disorder
Ketamine infusion has been shown to have rapid antidepressant properties, however the possible use of ketamine in treatment-resistant depression as augmentation has not been investigated.
- Trial name
- NCT01582945
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Cysteamine Therapy for Major Depressive Disorder
The purpose of this study is to determine whether cysteamine bitartrate, an FDA-approved drug for a non-psychiatric condition, is safe and effective for the treatment of major depression.
- Trial name
- NCT00715559
- Testing
- cysteamine bitartrate
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant
Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD
This a Phase 2a, multicenter, randomized, double-blind, placebo controlled 3 arm study to assess the safety and tolerability of multiple oral doses of REL-1017 25 mg and 50 mg as adjunctive therapy in the treatment of patients…
- Trial name
- NCT03051256
- Testing
- REL-1017
- Where
- 10 sites in United States
- Volunteers
- 62 people
- Sponsor
- Relmada Therapeutics, Inc.
Treatment-resistant Depression
Slow Wave Induction by Propofol to Eliminate Depression (SWIPED) I
Our hypothesis is that targeted propofol infusion in treatment-resistant depressed patients will induce slow wave activity during sedation and augment subsequent sleep slow wave activity.
- Trial name
- NCT04680910
- Testing
- Propofol, Electroencephalography (EEG), Slow-Wave Activity
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Washington University School of Medicine